LiquiVent: Started two 250-patient placebo controlled pivotal Phase II/III trials in the U.S. and Canada.

Primary end point is the number of days patients are off the ventilator at 28 days. Secondary end points include lung oxygenation, lung mechanics and lung elasticity. The trial is expected to last abo...